Table 5.

Prognostic value of the histological staging system applied to invasive CMCs.

Multivariate analyses		Disease-free interval		Overall survival		Cancer-specific survival
		HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Histological stage	IIIB vs. I	3.60 (2.22–5.85)	<0.0001	3.59 (2.55–5.04)	<0.0001	4.47 (2.81–7.11)	<0.0001
	IIIA vs. I	2.66 (1.61–4.37)	0.0001	2.27 (1.59–3.23)	<0.0001	2.98 (1.85–4.79)	<0.0001
	II vs. I	0.84 (0.46–1.52)	0.5686	1.46 (1.02–2.09)	0.0376	1.28 (0.75–2.16)	0.3536
Multicentricity	Single vs. multiple	–	NS	0.60 (0.44–0.82)	0.0017	–
Tumor-associated inflammation	Moderate to severe vs. absent to mild	–	NS	1.27 (1.01–1.60)	0.0409	1.42 (1.05–1.90)	0.0228
Histological grade	III vs. I–II	–	NS	1.30 (1.01–1.66)	0.0369	1.39 (1.00–1.92)	0.0469
Ki-67	≥20% vs. <20%	1.70 (1.00–2.88)	0.0470	–	NS	–	NS
	Triple-negative vs. luminal	1.64 (1.05–2.56)	0.0273	–	NS	–	NS

NS, not significant.